Adrian R. Krainer
CIK: 0001780081
Associated companies
Transaction History
| STOK | ▼ Sell | Open Market | 33,243 | $1.3M | 3/10/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 7,229 | $287K | 3/2/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 40,472 | $1.2M | 11/24/2025 | View on chart |
| STOK | ▼ Sell | Open Market | 19,790 | $527K | 11/14/2025 | View on chart |
| STOK | ▼ Sell | Open Market | 20,682 | $565K | 11/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.